Jiménez HF, Douriet MFA, Salgado AMC

Language: Spanish
References: 21
Page: 100-105
PDF size: 304.81 Kb.

ABSTRACT

Maggot therapy consists of the application of fly larvae in injuries for debridement, disinfection and healing. It has been used for hundreds of years in different cultures. The surgeon William Baer is considered the founder of modern maggot therapy. Between 1930 and 1940 it had a boom and virtually disappeared in the mid 1940s. At the end of the 1980s and early 1990s its use restarted. The larvae of the fly Lucilia (Phaenicia) sericata species are the most used. This therapy has been shown to decrease size of ulcers, exudates and necrotic tissue as well as pain and odor. The larvae act through debridement, disinfection and production of granulation tissue. Maggot therapy has been used on ulcers by pressure, diabetic foot ulcers, bedsores ulcers, venous ulcers, osteomyelitis, infections of surgical wounds and burns, among others. The larvae can be included in a small bag or free, directly on the wound. Maggot therapy is a good choice in wounds that do not respond adequately to conventional treatments.

REFERENCES

1. Sherman RA. Maggot therapy takes us back to the future of wound care: new and improved maggot therapy for the 21st century. J Diabetes Sci Technol. 2009; 3: 336-344.

2. Acton C. A know-how guide to using larval therapy for wound debridement. Wound Essentials. 2007; 2: 156-159.

3. Whitaker IS et al. Larval therapy from antiquity to the present day: mechanisms of action, clinical applications and future potential. Postgrad Med J. 2007; 83: 409-413.

4. Gottrup F, Jorgensen B. Maggot debridement: An alternative method for debridement. ePlasty. 2011; 11: 291-302.

5. Chan DC et al. Maggot debridement therapy in chronic wound care. Hong Kong Med J. 2007; 13: 382-6

6. Nigam Y et al. Maggot therapy: the science and implication for CAM. Part 1-History and bacterial resistance. eCAM. 2006; 3(2): 223-227

7. Steenvoorde P et al. Maggot debridement therapy of infected ulcers: patient and wound factors influencing outcome-A study of 101 patients with 117 wounds. Ann R Coll Surg Engl. 2007; 89: 596-602.

8. Paul AG et al. Maggot debridement therapy with Lucilia cuprina: a comparison with conventional debridement in diabetic foot ulcers. Int Wound J. 2009; 6: 39-46.

9. Joesphia KH. Cutaneous myasis: Is Lucilia cuprina safe and acceptable for maggot debridement therapy? JCDSA. 2012; 2: 79-82.

10. Dumbville JC et al. Larval therapy for leg ulcers (VenUS): randomized controlled trial. BMJ. 2009; 338: b773. Doi: 10.1136/bmj.b773.

11. Wolff H, Hansson C. Larval therapy-an effective method of ulcer debridement. Clin Exp Dermatol. 2003; 28: 134-137.

12. Opletalová K et al. Maggot therapy for wound debridement. Arch Dermatol. 2012; 148: 432-438.

13. Bekins L. Maggot therapy for removal of non-healing wounds. School of Physician Assistant Studies. 2010; 218: 1-21.

14. Parnés A, Lagan KM. Larval therapy in wound management. Int J Clin Pract. 2007; 61: 488-493.

15. Hunter S et al. Maggot therapy for wound management. Adv Skin Wound Care. 2009; 22: 25-27.

16. Marineau ML el at. Maggot debridement therapy in the treatment of complex diabetic wounds. Hawaii Med J. 2011; 70: 121-124.

17. Nigam Y et al. Maggot therapy: the science and implication for CAM. Part II- Maggots combat infection. eCAM. 2006; 3: 303-308.

18. Andersen AS et al. A novel approach to the antimicrobial activity of maggot debridement therapy. J Antimicrob Chemother. 2010; 65: 1646-1654.

19. Van der PA. Maggot secretions suppress proinflammatory responses of human monocytes through elevation of cyclic AMP. Diabetologia. 2009; 52: 1962-1970.

20. Wang S et al. Clinical research on the biodebridement effect of maggot therapy for treatment of chronically infected lesions. Orthopaedic Surgery. 2010; 2: 201-206.

21. Petherick ES et al. Patient acceptability of larval therapy for leg ulcer treatment: a randomized survey to inform the sample size calculation of a randomized trial. BMC Medical Research Methodology. 2006; 6: 43.